(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Wizz CEO: We’re going to invest $1 b. in Israeli market- 7 Methods for further developing Rest Quality
- Overhaul Your Rest: Tips for a Serene Evening
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- Supportive Tips On Home loans For First-Time Home Purchasers
- Best Wellness Tracker Keep You On target
- 'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
- Which Breakfast Enraptures Your Taste Buds? Vote
- The most effective method to Look at Medical caretaker Compensations Across Various Clinics
